Join Now

Contact

We Welcome Inquiries, Membership Applications, And Partnerships.

Mailing Address

Faravahar Heme-Onc Alliance San
Antonio, Texas, USA

General Contact

info@farahvar.org

Membership &
Scientific Exchange

membership@farahvar.org

This field is for validation purposes and should be left unchanged.
  • MEMBERSHIP

Join The Faravahar Heme-Onc Alliance

Membership in FHOA is open to all Persian and Persian-affiliated professionals in hematology and oncology.

Membership Levels

  • Medical Students, Residents, Fellows — Free Membership
  • Physicians & Researchers — Annual Dues To Support Educational Programs, Conferences, And Charitable Missions
  • Associate / Honorary Members — By Invitation

Member Benefits

  • Access To International Professional Networking
  • Mentorship And Career Development Opportunities
  • Participation In Research Collaborations
  • Invitations To Educational Events And Cultural Gatherings
  • Opportunity to contribute to humanitarian medical outreach

“whether You Are A Student Beginning Your Journey Or A Senior Physician Shaping The Field, The Faravahar Heme-onc Alliance Offers A Community Rooted In Persian Identity, Global Science, And Service.”

  • Latest Articles

Latest Articles

Nonprofit Status: Application for 501(c)(3) recognition has been submitted, EIN obtained in the State of Texas.

Bylaws: The governing document of the Alliance, ensuring transparency, accountability, and alignment with the mission. Articles include:

The Faravahar Heme-onc Alliance (Fhoa) Is Structured As A Nonprofit, Charitable, And Educational Organization.

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.
Learn More

Tumor-Infiltrating Clonal Hematopoiesis

Reveals that clonal hematopoiesis mutations within tumor microenvironments worsen outcomes — uniting hematology and solid tumor biology.
Learn More

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

DLL3-targeted bispecific T-cell engager delivers the first real survival breakthrough in SCLC in decades — new benchmark for immuno-engagers.
Learn More

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

Transforms a historically lethal subset into a treatable disease with targeted triplet therapy; establishes new first-line standard.
Learn More

Nonoperative Management of Mismatch Repair-Deficient Tumors

Immunotherapy replaces surgery for localized dMMR cancers — a paradigm shift proving organ preservation with 100% complete response rate.
Learn More

How Close Are We to Achieving Durable and Efficacious Gene Therapy for Hemophilia A and B?

Extended follow-up of pegcetacoplan and new oral factor D inhibitors confirms near-complete hemolysis control with improved quality of life.
Learn More

Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy

Long-term data showing sustained endogenous FVIII expression and reduced annualized bleed rates; establishes gene therapy as durable disease modification.
Learn More

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

First telomerase inhibitor to significantly improve transfusion independence in ESA-refractory MDS — now a frontline option before luspatercept failure.
Learn More

Can Early Intervention Prevent Leukemia? New Trial Gives Patients a Choice Beyond the Current ‘Wait and See’ Approach

Prospective cohort demonstrating that targeted anti-inflammatory therapy in high-risk CHIP carriers reduces progression to AML/MDS. Bridges genomics, inflammation, and prevention.
Learn More

Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and β-thalassemia: A current review

Landmark long-term follow-up showing durable transfusion independence and reversal of vaso-occlusive crises with exa-cel and related CRISPR therapies — functional cures achieved.
Learn More

A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphoma

Synthesizes 25 years of MSC trials; supports their safety and potential role in engraftment enhancement and immune modulation — a window into future graft engineering.
Learn More

Mesenchymal stem cell infusion to accelerate hematopoietic recovery after transplantation: A comprehensive systematic review of clinical studies (2000–2025)

High-impact registry data showing comparable long-term outcomes in auto- vs allo-SCT; informs decision-making in lymphoid malignancies.
Learn More

NCCN Clinical Practice Guidelines: Hematopoietic Cell Transplantation, Version 3.2025

Updated protocols for pre-HCT evaluation, GVHD prophylaxis, conditioning, and survivorship care. Core framework for quality and accreditation standards.
Learn More

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

Recommendations Comprehensive update from EBMT harmonizing transplant indications with modern cellular and gene therapies. Essential reference for transplant program strategy and clinical justification.
Learn More

Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR

Defines the new era of donor choice — prioritizing younger donors, clinical factors, and parallel donor searches rather than rigid HLA hierarchy. A practice-changing guideline for all transplant centers.
Learn More